J&J Poised To Establish No-Strings Attached JLABS Outside America

As J&J announced the establishment of its eighth JLABS facility, Melinda Richter, head of J&J Innovation, JLABS, says that the company is actively looking to establish JLABS in Europe and Asia.

Video interview
JLABS tells Scrip of expansion plans

As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovation, JLABS, tells Mike Ward that the company is actively looking to establish JLABS in Europe and Asia with an expectation that there will be news on this front in the near future.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from Scrip

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.